account/PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa �� (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with all AARP Medicare Part D plans through its pharmacy benefits...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pradaxa�� (dabigatran Etexilate Mesylate) Capsules Gains Preferred Formulary Status With AARP��, Nation's Largest Provider Of Medicare Part D Coverage
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account